Glossary of Peptide & Clinical Terms: A Reader's Reference

Across this site, efficacy statements carry an evidence grade so you can separate proven in humans from promising in a petri dish from marketing. This reference collects the vocabulary those grades and monographs rely on. It is informational and educational content, not medical advice, not a prescription or protocol, and not a sourcing or buying guide. Many peptides discussed in this field are not FDA-approved, are sold as research chemicals "not for human consumption," and/or are prohibited in sport. Where dosing or routes are mentioned, they are reported as described in the published literature for definitional completeness only.

What is a peptide, and how is it different from a protein?

A peptide is a short chain of amino acids — the monomer building blocks joined head-to-tail by peptide bonds (the covalent amide linkage between one amino acid's carboxyl group and the next one's amino group). A single amino-acid unit within an assembled chain is a residue, which is how chain length is counted. Because there is no universal scientific cutoff, the U.S. FDA adopted a regulatory threshold: any alpha-amino-acid polymer of 40 residues or fewer is treated as a peptide (regulated as a drug), and anything greater than 40 is a protein, regulated as a biologic.1 You can read the FDA's own reasoning in the 2018 Federal Register definition of a biological product, which notes that, other than size, no precise structural attribute cleanly separates the two.1

On this basis semaglutide (31 amino acids), leuprolide (9), and octreotide (8) are peptide drugs, while even insulin (51 amino acids) was reclassified as a biologic in 2020.2 A small molecule, by contrast, is a low-molecular-weight (typically under 1,000 Da) chemically synthesized drug; peptides occupy a middle ground between small molecules and larger biologics.2 An analog is a molecule structurally modified from a parent compound to change its properties — GLP-1 analogs such as liraglutide and semaglutide are nearly identical to native GLP-1 but engineered to extend half-life.13 Endogenous substances are made inside the body (ghrelin, GLP-1, IGF-1); exogenous ones are introduced from outside; and recombinant molecules are produced by genetically engineered cells rather than by synthesis or extraction.11

How do peptides act on receptors, and what do the pharmacology terms mean?

A receptor is a protein — often on the cell surface — that a signaling molecule (a ligand) binds to, triggering a biological response. Many peptide hormones act on G-protein-coupled receptors (GPCRs), seven-transmembrane proteins that convert an outside binding event into an inside signal.8 How a ligand behaves once bound is the crux of pharmacology.

These distinctions come from standard pharmacology teaching: agonists, partial agonists, and antagonists differ in intrinsic activity, while affinity, potency, and efficacy are measured separately — two drugs can be equally efficacious yet differ in potency.56 A drug's safety margin is its therapeutic index (roughly the toxic dose over the effective dose), and dosing aims to keep concentrations inside the therapeutic window.6 Continued stimulation can blunt a receptor: desensitization is a rapid drop in responsiveness (via receptor phosphorylation, beta-arrestin binding, and internalization), downregulation is an actual reduction in receptor number, tachyphylaxis is rapid loss of response after repeated dosing, and tolerance is the slower, days-to-weeks version — the reason some peptide protocols cycle or pulse dosing.7

What are the growth-hormone and metabolic peptide terms?

The growth-hormone axis is a common source of confusion. Growth hormone (GH) is released from the pituitary under two opposing hypothalamic signals: GHRH (stimulatory) and somatostatin (inhibitory).8 A secretagogue is anything that induces secretion of another substance; a growth hormone secretagogue is the umbrella term for compounds that raise GH, including GHRH-receptor agonists (sermorelin, CJC-1295, tesamorelin), ghrelin-receptor agonists (the GHRPs, hexarelin, ipamorelin), and the oral non-peptide ibutamoren.9 The GHSR (ghrelin receptor) is the GPCR whose natural ligand is ghrelin, the "hunger hormone"; in healthy men GHRP-2, like ghrelin, increases both GH and food intake.10 IGF-1, a 70-amino-acid peptide, is the principal downstream mediator of GH: GH stimulates the liver to make IGF-1, which drives anabolic and growth effects — the classic GH-IGF-1 axis.11

On the metabolic side, GLP-1 is an incretin gut hormone released after eating that boosts glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite; its native half-life is under 1.5 minutes because the enzyme DPP-4 rapidly degrades it.14 A GLP-1 receptor agonist (incretin mimetic) is engineered to resist DPP-4 and extend dosing to daily or weekly — the class behind semaglutide and the dual GIP/GLP-1 agonist tirzepatide, whose weight-loss and cardiovascular benefits are Grade A from large human trials.13 In the extracellular-matrix world, a matrikine (or matricryptin) is a peptide fragment liberated from the matrix that regulates cell activity; the copper tripeptide GHK-Cu is a canonical example whose wound-healing evidence remains largely preclinical (Grade C).12

What do the pharmacokinetic and dosing abbreviations mean?

Pharmacokinetics (PK) is what the body does to a drug, summarized by ADME: absorption, distribution, metabolism, excretion.3 Pharmacodynamics (PD) is the reverse — what the drug does to the body. The numbers you see in monographs come from PK: half-life (t½) is the time for a plasma concentration to fall by half and sets dosing frequency; Cmax is the peak concentration and Tmax the time it is reached; AUC (area under the curve) captures total exposure; and bioavailability (%F) is the fraction reaching circulation intact and active.3 Intravenous delivery is 100 percent bioavailable by definition, but because of the first-pass effect — loss to liver and gut metabolism before reaching circulation — oral peptide bioavailability is typically under 1 to 5 percent, which is why subcutaneous injection is the dominant route.415 A depot effect is slow, sustained release from an injection site or an albumin-binding analog, allowing less frequent dosing.13

What do the manufacturing, quality, and legal terms mean?

Most research and therapeutic peptides are shipped lyophilized (freeze-dried) — frozen, then dried under vacuum to a stable "cake" that resists hydrolysis — and must be reconstituted with a diluent before use, gently, to protect the peptide.16 The diluent is often bacteriostatic water (containing 0.9 percent benzyl alcohol, which inhibits bacterial growth and permits multi-dose vials) or preservative-free sterile water for single use.17 Quality is documented on a Certificate of Analysis (COA) — batch-specific identity, purity, potency, and sterility data — and governed by USP monographs and cGMP, the FDA-enforced current Good Manufacturing Practice regulations under 21 CFR 210-211.1819 The active substance itself is the API, which must be made in compliance with cGMP under ICH Q7 expectations.20 A product labeled "research use only" is a laboratory reagent — not made to pharmaceutical cGMP, not tested for human use, and carrying no FDA approval; the label does not make a product legal or safe to take.21

Legally, a peptide may be an FDA-approved drug, a compounded preparation, or an unapproved research chemical. The Drug Quality and Security Act created two compounding tracks: 503A traditional pharmacies (patient-specific, state-overseen, exempt from full cGMP) and 503B outsourcing facilities (FDA-registered, large batches allowed, full cGMP, direct inspection).22 To compound from a bulk substance under 503A, that substance must clear the FDA's evaluation — the interim policy sorts nominees into Category 1 (usable while under review) and Category 2 (significant safety concerns, may not be used).23 In late 2023 the FDA moved roughly 19 peptides, including BPC-157 and TB-500, to Category 2; some were later removed as nominations were withdrawn — but removal from Category 2 does not equal approval or Category 1 status.2425

Finally, sport has its own rules. The WADA Prohibited List places most peptide hormones in category S2 — banned in and out of competition — with an "and related substances" clause broad enough to catch novel analogs.27 Use is permitted only through a rarely granted Therapeutic Use Exemption (TUE), and under strict liability an athlete is responsible for anything found in their sample regardless of how it arrived.2628

Bottom line. The vocabulary of this field encodes real, load-bearing distinctions — a 40-amino-acid legal line, an agonist versus a blocker, a validated cGMP API versus a research-chemical vial, an FDA-approved drug versus a Category-2 bulk substance, an S2-prohibited hormone versus a permitted one. Knowing the words is the first step to reading the evidence honestly. Regulatory facts here are current as of June 2026 and should be re-verified, because they change.